Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-06

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation of patients on mechanical ventilation.

The main objectives of this study are:

* Evaluation of the clinical and antibacterial efficacy of the drug Fluorothiazinone in combination with standard measures for the prevention of nosocomial infections compared to placebo in combination with standard measures for the prevention of nosocomial infections for the prevention of nosocomial infections caused by bacterial gram-negative flora in patients on mechanical ventilation.
* Evaluation of the safety and tolerability of the drug Fluorothiazinone in patients on mechanical ventilation.
* Evaluation of the pharmacokinetics (in whole blood) of the drug Fluorothiazinone with a single daily dose of 2400 mg/day.

Researchers will compare results for the treatment and the placebo arms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Teeth Brushing in Ventilated COVID-19 Patients.

NCT05575050

Microbial Colonization COVID-19 Respiratory Infection Dysbiosis +2 more

COMPLETED NA

Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

NCT02574130

Pneumonia, Ventilator-Associated

COMPLETED NA

Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria

NCT04839653

Pneumonia, Ventilator-Associated Pneumonia Bloodstream Infection +4 more

UNKNOWN NA

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643

Respiratory Infection Bacterial Resistance Respiratory Failure

COMPLETED EARLY_PHASE1

The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia

NCT04325685

Trauma Injury Brain Injuries Abdominal Sepsis +5 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gram Negative Pneumonia Gram-Negative Bacterial Infections Bacteremia Caused by Gram-Negative Bacteria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment arm

Group Type EXPERIMENTAL

Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day

Intervention Type DRUG

Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:

* 2400 mg/day (4 tablets twice a day) for the first 2 days and;
* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.

Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Placebo arm

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo arm patients will receive placebo:

* 4 tablets twice a day for the first 2 days and;
* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.

Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day

Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:

* 2400 mg/day (4 tablets twice a day) for the first 2 days and;
* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.

Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Intervention Type DRUG

Placebo

Placebo arm patients will receive placebo:

* 4 tablets twice a day for the first 2 days and;
* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.

Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient's written consent to participate in the study in accordance with the current legislation or the decision of the board in case of absence of consciousness of the patient.
2. Patients are at least 18 years old, male and female.
3. Patients who are in the ICU (intensive care unit).
4. Patients with:

4.1. Laboratory confirmed SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus-2) on screening (a patient's coronavirus infection can be confirmed either before admission to the hospital (for outpatient treatment) or when admitted to the hospital) by RT-PCR (reverse transcription polymerase chain reaction) AND severe community-acquired pneumonia in ICU with evidence of viral lung injury and symptoms of respiratory failure:
* SpO2 (peripheral oxygen saturation) ≤ 93%;
* Lung changes of 3rd- to 4th-degree according to CT (results of computed tomography), consistent with viral involvement; OR 4.2. Acute stroke; OR 4.3. Acute heart failure: Cardiogenic shock of any cause, pulmonary edema, or acute decompensated chronic heart failure.
5. Patients who have been on ALV (artificial lung ventilation) for no more than 12 hours.
6. Patients who are according to the investigator are at high risk to be transferred to ALV within 72 hours of the initiation of the therapy.
7. All women of childbearing age and men with partners of childbearing age should agree to use an effective contraceptive methods (e.g., implants, infections, combination oral contraceptives, intrauterine device, abstinence, vasectomy or vasectomy partner) during the entire study.

Exclusion Criteria

1. The patient was not switched to ALV within 72 hours (3 days) after receiving the investigational drug.
2. People who have a bloodstream infection, identified during the screening.
3. A patient may terminate his/her participation in the study at any time for any reason and without any explanation.

3\. The investigator may also decide to terminate the patient's participation at any time if it is required due to the patient's condition.

4\. The sponsor or the regulator may also request the trial to be terminated early, either due to how the trial was conducted, or due to application safety data, or other reasons.

5\. The main reasons why the patient may withdraw from the study are:

* Refusal of the patient to participate in the study;
* Development of an AE (adverse event) / SAE (serious adverse event) that prevents further study participation;
* The occurrence of concomitant somatic diseases / symptoms or exacerbation of chronic diseases not related to the investigational drug (at the discretion of the medical investigator).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No